Aditya Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aditya Singh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Amita Verma
Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India
3 shared publications - Juber Akhtar
Faculty of Pharmacy, Integral University, Lucknow, India
2 shared publications - Shubhrat Maheshwari
Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India
2 shared publications - Tarique Mahmood
Department of Pharmacy, Integral University, Lucknow, India
2 shared publications Akash Singh
Maharishi School of Pharmaceutical Sciences, MUIT, Lucknow, India
1 shared publication- Bhupendra Gopalbhai Prajapati
Parul University
1 shared publication
Latest Publications
- 19 August 2026
- Published by Springer Nature in Biomedical Materials & Devices
- p. 1-49
Carbon Quantum Dots in Biomedicine: Synthesis, Surface Engeering, and Clinical Translation
- 19 August 2026
- Published by Springer Nature in Biomedical Materials & Devices
- p. 1-49
Carbon Quantum Dots in Biomedicine: Synthesis, Surface Engeering, and Clinical Translation
- Open Access
- 22 July 2026
- Published by Wolters Kluwer Health in Journal of The Egyptian Society of Nephrology and Transplantation
- Vol. 26 (3) , 121-142
Diabetic nephropathy: pathophysiology, biomarkers and treatment strategies
Diabetic nephropathy (DN) is a major complication of diabetes mellitus and a leading cause of chronic kidney disease and renal failure globally. This review comprehensively summarizes the pathophysiology, biomarkers, and therapeutic strategies of DN. Chronic hyperglycemia and dyslipidemia activate oxidative, inflammatory, fibrotic, and endothelial dysfunction pathways that drive disease progression. Key mediators such as advanced glycation end-products, transforming growth factor-β, protein kinase C, and the renin–angiotensin–aldosterone system contribute to glomerular injury, podocyte loss, and tubulointerstitial fibrosis. Emerging biomarkers, including Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-β-D-glucosaminidase, and podocyte-specific proteins, enable early detection and personalized management. Immune cells (macrophages, lymphocytes) and cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-18) further amplify renal inflammation and damage. Therapeutic interventions such as renin–angiotensin–aldosterone system blockers, sodium-glucose cotransporter-2 inhibitors, and anti-inflammatory or antioxidant agents demonstrate promise in delaying disease progression. This review also highlights recent insights into nanotechnology-based drug delivery and emerging molecular targets that could shape next-generation therapies for DN. Molecular and cellular mechanisms underlying diabetic nephropathy. Hyperglycemia induces oxidative stress, mitochondrial dysfunction, and activation of signaling pathways, including nuclear factor-κB, Janus kinase/signal transducer and activator of transcription, transforming growth factor-β, and protein kinase C. Crosstalk between mesangial, endothelial, and tubular epithelial cells promotes inflammation, extracellular matrix accumulation, and fibrosis.
- 22 July 2026
- Published by Wolters Kluwer Health in Journal of The Egyptian Society of Nephrology and Transplantation
- Vol. 26 (3) , 121-142
Open AccessDiabetic nephropathy: pathophysiology, biomarkers and treatment strategies
Diabetic nephropathy (DN) is a major complication of diabetes mellitus and a leading cause of chronic kidney disease and renal failure globally. This review comprehensively summarizes the pathophysiology, biomarkers, and therapeutic strategies of DN. Chronic hyperglycemia and dyslipidemia activate oxidative, inflammatory, fibrotic, and endothelial dysfunction pathways that drive disease progression. Key mediators such as advanced glycation end-products, transforming growth factor-β, protein kinase C, and the renin–angiotensin–aldosterone system contribute to glomerular injury, podocyte loss, and tubulointerstitial fibrosis. Emerging biomarkers, including Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-β-D-glucosaminidase, and podocyte-specific proteins, enable early detection and personalized management. Immune cells (macrophages, lymphocytes) and cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-18) further amplify renal inflammation and damage. Therapeutic interventions such as renin–angiotensin–aldosterone system blockers, sodium-glucose cotransporter-2 inhibitors, and anti-inflammatory or antioxidant agents demonstrate promise in delaying disease progression. This review also highlights recent insights into nanotechnology-based drug delivery and emerging molecular targets that could shape next-generation therapies for DN. Molecular and cellular mechanisms underlying diabetic nephropathy. Hyperglycemia induces oxidative stress, mitochondrial dysfunction, and activation of signaling pathways, including nuclear factor-κB, Janus kinase/signal transducer and activator of transcription, transforming growth factor-β, and protein kinase C. Crosstalk between mesangial, endothelial, and tubular epithelial cells promotes inflammation, extracellular matrix accumulation, and fibrosis.
- 16 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (8) , 1-22
Superparamagnetic iron oxide nanoparticles (SPIONs) in targeting brain tumors: advances and challenges
Brain tumors are among the most lethal forms of cancer, often presenting treatment challenges due to the complexity of the central nervous system and the restrictive nature of the blood–brain barrier (BBB). Superparamagnetic iron oxide nanoparticles (SPIONs) have emerged as promising agents in neuro-oncology due to their unique magnetic properties, biocompatibility, and multifunctional capabilities. SPIONs serve as potent contrast agents in magnetic resonance imaging (MRI), drug delivery vehicles, and hyperthermia mediators. Their ability to be functionalized with ligands and antibodies allows for targeted delivery, minimizing systemic toxicity and enhancing therapeutic precision. Moreover, SPIONs have shown potential in modulating immune responses, disrupting tumor microenvironments, and improving the delivery of chemotherapeutics across the BBB. Despite encouraging preclinical outcomes and some early-phase clinical trials, challenges such as biodistribution control, toxicity, and manufacturing scalability remain. This review highlights the current landscape of SPION applications in brain tumor therapy and diagnosis, elaborating on their synthesis, functionalization, and translational hurdles. We also discuss future directions, including AI-guided theranostics, personalized nanomedicine, and integration with immunotherapy, aiming to illuminate the path forward for SPION-based clinical interventions. Graphical Abstract SPIONs for Diagnosis and Therapy of Brain Tumors
- 16 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (8) , 1-22
Superparamagnetic iron oxide nanoparticles (SPIONs) in targeting brain tumors: advances and challenges
Brain tumors are among the most lethal forms of cancer, often presenting treatment challenges due to the complexity of the central nervous system and the restrictive nature of the blood–brain barrier (BBB). Superparamagnetic iron oxide nanoparticles (SPIONs) have emerged as promising agents in neuro-oncology due to their unique magnetic properties, biocompatibility, and multifunctional capabilities. SPIONs serve as potent contrast agents in magnetic resonance imaging (MRI), drug delivery vehicles, and hyperthermia mediators. Their ability to be functionalized with ligands and antibodies allows for targeted delivery, minimizing systemic toxicity and enhancing therapeutic precision. Moreover, SPIONs have shown potential in modulating immune responses, disrupting tumor microenvironments, and improving the delivery of chemotherapeutics across the BBB. Despite encouraging preclinical outcomes and some early-phase clinical trials, challenges such as biodistribution control, toxicity, and manufacturing scalability remain. This review highlights the current landscape of SPION applications in brain tumor therapy and diagnosis, elaborating on their synthesis, functionalization, and translational hurdles. We also discuss future directions, including AI-guided theranostics, personalized nanomedicine, and integration with immunotherapy, aiming to illuminate the path forward for SPION-based clinical interventions. Graphical Abstract SPIONs for Diagnosis and Therapy of Brain Tumors
- 10 January 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 94, 102193
Navigating the dementia landscape: Biomarkers and emerging therapies
- 10 January 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 94, 102193
Navigating the dementia landscape: Biomarkers and emerging therapies
- Open Access
Entanglement of AGE-RAGE axis in cardiac pathosis
Cardiovascular diseases are the major cause of death globally. Acute coronary syndrome is one of numerous cardiovascular illnesses, including advanced glycation end products (AGEs), which play an instrumental part in their development and progression. A substance with multiple pleiotropic characteristics is rosuvastatin. This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. Rosuvastatin (10 mg/kg, orally) was given to male rats daily for 4 weeks, and on the 29th and 30th days, isoproterenol (85 mg/kg, subcutaneously) was administered to cause cardiac damage. Rats were euthanised on the 31st day, and various samples were collected for examination. Administration of isoproterenol increased cardiac mass, levels of cardiac damage markers, lipid oxidation, and collagen content in the heart. Additionally, it reduced the activities of SOD, CAT, GST, GR, and all other antioxidants. Additionally, isoproterenol raises levels of inflammatory markers including TNF-α and IL-6. It has been observed that advanced glycation end products rise along with heart injury. The AGE-RAGE cascade also messes with the injured heart’s echocardiogram. Additionally, histopathological alterations were noticed. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by an array of physical, biochemical, and histological characteristics. Summary This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by a number of physiological, biochemical, and histological characteristics. By showing how the functional AGE/RAGE axis is inhibited following rosuvastatin medication, this work provides an etiologic theory involving rosuvastatin therapy in heart injury. These findings may also have practical significance since they highlight the intriguing possibility that rosuvastatin-induced modulation of AGE-RAGE signalling may represent a unique therapeutic approach for the prevention and treatment of other cardiovascular diseases.
Open AccessEntanglement of AGE-RAGE axis in cardiac pathosis
Cardiovascular diseases are the major cause of death globally. Acute coronary syndrome is one of numerous cardiovascular illnesses, including advanced glycation end products (AGEs), which play an instrumental part in their development and progression. A substance with multiple pleiotropic characteristics is rosuvastatin. This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. Rosuvastatin (10 mg/kg, orally) was given to male rats daily for 4 weeks, and on the 29th and 30th days, isoproterenol (85 mg/kg, subcutaneously) was administered to cause cardiac damage. Rats were euthanised on the 31st day, and various samples were collected for examination. Administration of isoproterenol increased cardiac mass, levels of cardiac damage markers, lipid oxidation, and collagen content in the heart. Additionally, it reduced the activities of SOD, CAT, GST, GR, and all other antioxidants. Additionally, isoproterenol raises levels of inflammatory markers including TNF-α and IL-6. It has been observed that advanced glycation end products rise along with heart injury. The AGE-RAGE cascade also messes with the injured heart’s echocardiogram. Additionally, histopathological alterations were noticed. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by an array of physical, biochemical, and histological characteristics. Summary This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by a number of physiological, biochemical, and histological characteristics. By showing how the functional AGE/RAGE axis is inhibited following rosuvastatin medication, this work provides an etiologic theory involving rosuvastatin therapy in heart injury. These findings may also have practical significance since they highlight the intriguing possibility that rosuvastatin-induced modulation of AGE-RAGE signalling may represent a unique therapeutic approach for the prevention and treatment of other cardiovascular diseases.